WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018027290) HETEROLOGOUS EXPRESSION CASSETTE, DNA CONSTRUCT AND VACCINE COMPOSITION FOR IMMUNIZING AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/027290    International Application No.:    PCT/BR2017/050221
Publication Date: 15.02.2018 International Filing Date: 04.08.2017
IPC:
C12N 15/86 (2006.01), C12N 15/40 (2006.01), C12N 15/66 (2006.01), A61K 39/12 (2006.01), C12N 7/01 (2006.01)
Applicants: FUNDAÇÃO OSWALDO CRUZ [BR/BR]; Av. Brasil 4365, Manguinhos 21045-900 Rio de Janeiro, RJ (BR)
Inventors: BONALDO, Myrna, Cristina; (BR).
LIMA, Noemia, Santana; (BR)
Agent: KASZNAR LEONARDOS PROPRIEDADE INTELECTUAL; Rua Teófilo Otoni 63, 5TH - 8TH Floors 20090-080 Rio de Janeiro, RJ (BR)
Priority Data:
BR102016018430-4 10.08.2016 BR
Title (EN) HETEROLOGOUS EXPRESSION CASSETTE, DNA CONSTRUCT AND VACCINE COMPOSITION FOR IMMUNIZING AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS
(FR) CASSETTE D’EXPRESSION HÉTÉROLOGUE, CONSTRUCTION D'ADN ET COMPOSITION VACCINALE POUR IMMUNISER CONTRE LE FLAVIVIRUS ET/OU D’AUTRES PATHOGÈNES
(PT) CASSETE DE EXPRESSÃO HETERÓLOGA, CONSTRUCTO DE DNA E COMPOSIÇÃO VACINAL PARA IMUNIZAR CONTRA FLAVIVIRUS E/OU OUTROS PATÓGENOS
Abstract: front page image
(EN)The present invention relates to DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses obtained. This invention also concerns an improvement made to the expression vector of the live attenuated virus of yellow fever 17D. The present invention provides for the introduction of modifications to the expression cassette of heterologous proteins in the intergenic region E/NS1 of the vaccine virus of yellow fever 17D. The two new functional domains inserted into the expression cassette were (1) a coding sequence for N-glycosylation motif, located between the N-terminal NS1 motif and the heterologous protein and (2) a sequence that promotes the proteolytic cleavage or otherwise of the recombinant protein in order to release same from the C-terminal of same containing the transmembrane domains and, consequently, from the association thereof with the membrane of the endoplasmic reticulum RE.
(FR)La présente invention concerne des constructions d'ADN, des virus recombinants et des compositions vaccinales contenant les virus recombinants obtenus. L'invention concerne également une amélioration du vecteur d'expression du virus vivant atténué de la fièvre jaune 17D. La présente invention prévoit d'apporter des modifications à la cassette d'expression de protéines hétérologues dans la région intergénique E/NS1 du virus vaccinal de la fièvre jaune 17D. Les deux nouveaux domaines fonctionnels insérés dans la cassette d'expression sont (1) une séquence codante pour motif de N-glycosylation, situé entre le motif N-terminal NS1 et la protéine hétérologue, et (2) une séquence favorisant le clivage protéolitique ou non de la protéine recombinante de manière à la libérer du C-terminal contenant les domaines transmembranaires et, par conséquent, de son association avec la membrane du réticulum endoplasmique RE.
(PT)A presente invenção se refere a constructos de DNA, vírus recombinantes e composições vacinais contendo os vírus recombinantes obtidos. Esta invenção trata, ainda, de um aperfeiçoamento do vetor de expressão do vírus vivo atenuado da febre amarela 17D. A presente invenção prevê a introdução de modificações no cassete de expressão de proteínas heterólogas na região intergênica E/NS1 do vírus vacinal da febre amarela 17D. Os dois novos domínios funcionais inseridos no cassete de expressão foram (1) uma sequência codante para motivo de N-glicosilação, localizado entre o motivo N-terminal NS1 e a proteína heteróloga e (2) uma sequência que promovesse a clivagem proteolítica ou não da proteína recombinante de modo a liberá-la do seu C-terminal contendo os domínios transmembranares e, por conseguinte, da sua associação com a membrana do retículo endoplasmático RE.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Portuguese (PT)
Filing Language: Portuguese (PT)